衰老细胞靶向治疗的抗癌作用研究进展

doi:10.3969/j.issn.1004-616x.2025.04.009

摘要/Abstract

摘要： 近年来，癌症的发生率和死亡率不断增加，严重威胁着人类健康。目前临床治疗方法包括手术治疗、化学治疗、放射放疗等，但是这些疗法副作用较大，严重降低了患者的生活质量。衰老微环境通过增强衰老相关分泌表型(SASP)的分泌、诱导免疫逃逸及促进细胞外基质(ECM)硬化3条途径驱动肿瘤侵袭、转移及耐药。衰老细胞靶向治疗能够通过清除衰老细胞或抑制SASP分泌改善癌症治疗。衰老细胞靶向治疗面临药物毒性、生物利用度低等挑战，未来需要对衰老细胞靶向治疗的给药策略展开深入研究，以便为基于衰老微环境的肿瘤治疗提供新的思路。

关键词: 衰老细胞, 靶向治疗, 衰老微环境, 衰老相关分泌表型, 衰老细胞裂解剂, 衰老细胞表型调节剂

中图分类号:

Q255

张伟洁, 李靖华, 刘寒, 刘光仪, 方雪妮, 张弛, 周天. 衰老细胞靶向治疗的抗癌作用研究进展[J]. 癌变·畸变·突变, 2025, 37(4): 292-295,299.

ZHANG Weijie, LI Jinghua, LIU Han, et al.. Research progress on anti-cancer effects of senescent cell targeted therapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 292-295,299.

参考文献

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA A Cancer J Clin, 2018, 68(1): 7-30.
[2] WANG L Q, LANKHORST L, BERNARDS R. Exploiting senescence for the treatment of cancer[J]. Nat Rev Cancer, 2022, 22(6): 340-355.
[3] RUHLAND M K, LOZA A J, CAPIETTO A H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis[J]. Nat Commun, 2016, 7: 11762.
[4] 郭茜晨, 张婷婷, 王润新, 等. 内质网应激反应IRE1α信号通路与细胞衰老在癌症中的作用及关系的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 72-76.
[5] 努尔斯曼古丽·买买提明, 张莉. 衰老微环境对肿瘤发生发展的影响及其机制[J]. 中国肿瘤生物治疗杂志, 2022, 29(8): 756-761.
[6] KIRSCH V, RAMGE J M, SCHOPPA A, et al. In vitro characterization of doxorubicin-mediated stress-induced premature senescence in human chondrocytes[J]. Cells, 2022, 11(7): 1106.
[7] AL-KHALAF H H, GHEBEH H, INASS R, et al. Senescent breast luminal cells promote carcinogenesis through interleukin-8-dependent activation of stromal fibroblasts[J]. Mol Cell Biol, 2019, 39(2): e00359-18.
[8] YASUDA T, KOIWA M, YONEMURA A, et al. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination[J]. Cell Rep, 2021, 34(8): 108779.
[9] SANTOLLA M F, TALIA M, CIRILLO F, et al. The AGEs/RAGE transduction signaling prompts IL-8/CXCR1/2-mediated interaction between cancer-associated fibroblasts (CAFs) and breast cancer cells[J]. Cells, 2022, 11(15): 2402.
[10] WANG T, NOTTA F, NAVAB R, et al. Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes[J]. Mol Cancer Res, 2017, 15(1): 3-14.
[11] LIU D, HORNSBY P J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion[J]. Cancer Res, 2007, 67(7): 3117-3126.
[12] TRZONKOWSKI P, SZMIT E, MY-LIWSKA J, et al. CD4⁺CD25⁺ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence[J]. Clin Immunol, 2006, 119(3): 307-316.
[13] TOSO A, REVANDKAR A, DI MITRI D, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity[J]. Cell Rep, 2014, 9(1): 75-89.
[14] LIAN J Y, YUE Y, YU W N, et al. Immunosenescence: a key player in cancer development[J]. J Hematol Oncol, 2020, 13(1): 151.
[15] 苏静, 胡以平. 肝纤维化发生及逆转途径的研究进展[J]. 癌变·畸变·突变, 2022, 34(3): 242-246.
[16] ZHU Y, TCHKONIA T, PIRTSKHALAVA T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs[J]. Aging Cell, 2015, 14(4): 644-658.
[17] TSE C, SHOEMAKER A R, ADICKES J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor[J]. Cancer Res, 2008, 68(9): 3421-3428.
[18] CHANG J H, WANG Y Y, SHAO L J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice[J]. Nat Med, 2016, 22(1): 78-83.
[19] SALEH T, CARPENTER V J, TYUTYUNYK-MASSEY L, et al. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL-BAX interaction[J]. Mol Oncol, 2020, 14(10): 2504-2519.
[20] FLEURY H, MALAQUIN N, TU V, et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence[J]. Nat Commun, 2019, 10: 2556.
[21] WANG L Q, LEITE DE OLIVEIRA R, WANG C, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer[J]. Cell Rep, 2017, 21(3): 773-783.
[22] KOLODKIN-GAL D, ROITMAN L, OVADYA Y, et al. Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions[J]. Gut, 2022, 71(2): 345-355.
[23] YOUSEFZADEH M J, ZHU Y, MCGOWAN S J, et al. Fisetin is a senotherapeutic that extends health and lifespan[J]. EBioMedicine, 2018, 36: 18-28.
[24] KANG K A, PIAO M J, KIM K C, et al. Fisetin attenuates hydrogen peroxide-induced cell damage by scavenging reactive oxygen species and activating protective functions of cellular glutathione system[J]. In Vitro Cell Dev Biol Anim, 2014, 50(1): 66-74.
[25] BOURGEOIS B, MADL T. Regulation of cellular senescence via the FOXO4-p53 axis[J]. FEBS Lett, 2018, 592(12): 2083-2097.
[26] TSAI K K C, STUART J, CHUANG Y E, et al. Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant[J]. Radiat Res, 2009, 172(3): 306-313.
[27] MENG J S, LI Y, WAN C, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis[J]. JCI Insight, 2021, 6(23): e146334.
[28] EWALD J A, DESOTELLE J A, WILDING G, et al. Therapy-induced senescence in cancer[J]. J Natl Cancer Inst, 2010, 102(20): 1536-1546.
[29] WANG L, XIONG B, LU W, et al. Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer[J]. Biomed Pharmacother, 2024, 174: 116474.
[30] XU M, PIRTSKHALAVA T, FARR J N, et al. Senolytics improve physical function and increase lifespan in old age[J]. Nat Med, 2018, 24(8): 1246-1256.
[31] SUN Y, WANG X, LIU T W, et al. The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities[J]. Cell Biosci, 2022, 12(1): 74.
[32] VéZINA C, KUDELSKI A, SEHGAL S N. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle[J]. J Antibiot (Tokyo), 1975, 28(10): 721-726.
[33] LABERGE R M, SUN Y, ORJALO A V, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation[J]. Nat Cell Biol, 2015, 17(8): 1049-1061.
[34] SARAN U, FOTI M, DUFOUR J F. Cellular and molecular effects of the mTOR inhibitor everolimus[J]. Clin Sci (Lond), 2015, 129(10): 895-914.
[35] FIELDER E, WAN T F, ALIMOHAMMADIHA G, et al. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice[J]. eLife, 2022, 11: e75492.
[36] ABDELGAWAD I Y, AGOSTINUCCI K, SADAF B, et al. Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells[J]. Front Aging, 2023, 4: 1170434.
[37] YANG D, SUN B, LI S R, et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman Primates[J]. Sci Transl Med, 2023, 15(709): eadd1951.
[38] ZHENG L Y, HE S P, WANG H, et al. Targeting cellular senescence in aging and age-related diseases: challenges, considerations, and the emerging role of senolytic and senomorphic therapies[J]. Aging Dis, 2024, 15(6): 2554-2594.
[39] MALAGUARNERA L. Influence of resveratrol on the immune response[J]. Nutrients, 2019, 11(5): 946.
[40] NADILE M, RETSIDOU M I, GIOTI K, et al. Resveratrol against cervical cancer: evidence from in vitro and in vivo studies[J]. Nutrients, 2022, 14(24): 5273.
[41] KIRKLAND J L, TCHKONIA T. Senolytic drugs: from discovery to translation[J]. J Intern Med, 2020, 288(5): 518-536.
[42] MALAYAPERUMAL S, MAROTTA F, KUMAR M M, et al. The emerging role of senotherapy in cancer: a comprehensive review[J]. Clin Pract, 2023, 13(4): 838-852.